PMID- 12200757
OWN - NLM
STAT- MEDLINE
DCOM- 20020926
LR  - 20190725
IS  - 0026-0495 (Print)
IS  - 0026-0495 (Linking)
VI  - 51
IP  - 9
DP  - 2002 Sep
TI  - Glycoxidized low-density lipoprotein enhances monocyte chemoattractant protein-1 
      mRNA expression in human umbilical vein endothelial cells: relation to 
      lysophosphatidylcholine contents and inhibition by nitric oxide donor.
PG  - 1135-42
AB  - Low-density lipoprotein (LDL) may undergo more glycation or oxidation in patients 
      with diabetes mellitus than in nondiabetic subjects. We investigated whether 
      glycoxidized LDL (goLDL) induces monocyte chemoattractant protein-1 (MCP-1) mRNA 
      expression through activation of nuclear factor-kappaB (NFkappaB), and determined 
      the effect of nitric oxide (NO) on MCP-1 mRNA expression in human umbilical vein 
      endothelial cells (HUVEC). Oxidized (oxLDL) or goLDL enhanced MCP-1 mRNA 
      expression in HUVEC, and preincubation with NOR3, a NO donor, abrogated such 
      stimulation. goLDL increased NFkappaB-DNA binding activity in HUVEC and this 
      effect was also suppressed by NOR3. We measured lysophosphatidylcholine (lyso-PC) 
      contents in modified LDL using electrospray ionization liquid chromatography/mass 
      spectrometry (LC/MS) to identify its molecular species. MCP-1 mRNA expression and 
      NFkappaB activation correlated significantly with palmitoyl- and stearoyl-lyso-PC 
      contents in LDL. Our results suggest that LDL modified by glycation and oxidation 
      may contribute to the development of accelerated atherosclerosis in the presence 
      of diabetes, a process that may be prevented by increased vascular NO 
      availability.
CI  - Copyright 2002, Elsevier Science (USA). All rights reserved.
FAU - Sonoki, Kazuo
AU  - Sonoki K
AD  - Department of Medicine and Clinical Science, Graduate School of Medical Sciences, 
      Kyushu University, Fukuoka, Japan.
FAU - Yoshinari, Mototaka
AU  - Yoshinari M
FAU - Iwase, Masanori
AU  - Iwase M
FAU - Iino, Kenzo
AU  - Iino K
FAU - Ichikawa, Kojiro
AU  - Ichikawa K
FAU - Ohdo, Shigehiro
AU  - Ohdo S
FAU - Higuchi, Shun
AU  - Higuchi S
FAU - Iida, Mitsuo
AU  - Iida M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Metabolism
JT  - Metabolism: clinical and experimental
JID - 0375267
RN  - 0 (Chemokine CCL2)
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (Lysophosphatidylcholines)
RN  - 0 (NF-kappa B)
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (Nitro Compounds)
RN  - 0 (RNA, Messenger)
RN  - 0 (oxidized low density lipoprotein)
RN  - 9007-49-2 (DNA)
RN  - 92454-60-9 (FK 409)
SB  - IM
MH  - Cells, Cultured
MH  - Chemokine CCL2/*genetics
MH  - DNA/metabolism
MH  - Endothelium, Vascular/cytology/*metabolism
MH  - Glycosylation
MH  - Humans
MH  - Lipoproteins, LDL/*metabolism/pharmacology
MH  - Lysophosphatidylcholines/metabolism
MH  - NF-kappa B/physiology
MH  - Nitric Oxide Donors/pharmacology
MH  - Nitro Compounds/pharmacology
MH  - Oxidation-Reduction
MH  - RNA, Messenger/antagonists & inhibitors/*metabolism
MH  - Umbilical Veins/cytology/*metabolism
EDAT- 2002/08/30 10:00
MHDA- 2002/09/27 06:00
CRDT- 2002/08/30 10:00
PHST- 2002/08/30 10:00 [pubmed]
PHST- 2002/09/27 06:00 [medline]
PHST- 2002/08/30 10:00 [entrez]
AID - S0026049502000550 [pii]
AID - 10.1053/meta.2002.34703 [doi]
PST - ppublish
SO  - Metabolism. 2002 Sep;51(9):1135-42. doi: 10.1053/meta.2002.34703.